Lobbying client · LD-2 disclosures
Collaborative for Evidence-Based Medicines
Indiana
0 filings from 0 registrants · 2026 · latest filed Jul 16, 2026
Reported on its behalf
$0
every LD-2 on file
Its own filed spend
$0
lobbying for itself
Fees to outside firms
$0
none reported
Bills named in the filings
Every bill reference extracted from the filings' activity descriptions.
- H.R. 6509 119th CongressSAFE Drugs Act of 20251 filingthrough 2026
- S. 3794 119th CongressSAFE Drugs Act of 20261 filingthrough 2026
How these are found · Bill references are extracted from the free-text activity description each filing writes, then matched to the Congress in session that filing year. A reference we can't match to a bill on file is still shown, unlinked — we cite what the filing said rather than guess at what it meant. Naming a bill is not a position on it: LD-2 records that a client lobbied on the bill, never which side.
Who did the lobbying
Every lobbyist named on this client's filings.
- Josh Andrews Faegre Drinker Biddle & Reath LLPCovered position: Legislative Assistant, Rep. Anna G. Eshoo (CA-14); Legislative Correspondent, Sen. Barbara Boxer (D-CA)1 filingthrough 2026
- Barrett Tenbarge Faegre Drinker Biddle & Reath LLP1 filingthrough 2026
Covered positions · 1 of 2 lobbyists named on these filings disclosed a prior government post. The text is reproduced exactly as filed.
The filings
Every filing on record. Each row links to its full disclosure.
This record groups every filed spelling of the client's name into one entity, so "MERCK & CO., INC." and "MERCK & CO INC" read as the same company. The grouping is the client's normalized name — organizations that file under genuinely different names appear separately. Handle: collaborative-for-evidence-based-medicines.